FDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis - Investors | Eli Lilly and Company

The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.

By: Lilly.com

Sep 14 2024
0
0 Views

EBGLYSS provides a new first-line biologic treatment for moderate-to-severe atopic dermatitis that is not well controlled with topicals Patients treated with EBGLYSS experienced significant skin cle… [+17275 chars]

DJT stock soars after Trump says he has "no intention of selling" his Trump Media shares - CBS News

Sam Bankman-Fried targets Sullivan & Cromwell in appeal against conviction - Financial Times

Stock Market Today: Investors Ramp Up Bets on Jumbo Fed Rate Cut - The Wall Street Journal

California is raising the stakes in the country’s gas stove controversy - SFGATE

Boar’s Head closing Virginia plant linked to deadly listeria outbreak - The Associated Press

Broncos are talking about Justin, Russ, T.J. and more - Steelers.com

Share this page

Guest Posts by Easy Branches

Banner advertising on easybranches network

all our websites